Nature Reviews Drug Discovery contents July 2016 Volume 15 Number 7 pp 441-516

If you are unable to see the message below, click here to view.

Advertisement
QScience.com Highlights is a regularly updated online platform which highlights the best of published research, handpicked by Nature Publishing Group editors, from QScience.com. Stay up-to-date with the latest research and reviews  qscience.nature.com
TABLE OF CONTENTS
July 2016 Volume 15 Number 7
Impact Factor 47.120 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month  Featured article: Altering the course of schizophrenia: progress and perspectives Mark J. Millan, Annie Andrieux, George Bartzokis, Kristin Cadenhead, Paola Dazzan, Paolo Fusar-Poli, Jürgen Gallinat, Jay Giedd, Dennis R. Grayson, Markus Heinrichs, Ren7eacute; Kahn, Marie-Odile Krebs, Marion Leboyer, David Lewis, Oscar Marin, Philippe Marin, Andreas Meyer-Lindenberg, Patrick McGorry, Philip McGuire, Michael J. Owen, Paul Patterson, Akira Sawa, Michael Spedding, Peter Uhlhaas, Flora Vaccarino, Claes Wahlestedt & Daniel Weinberger
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Work at Roche in Switzerland We're looking for committed scientists who share our passion to make a difference for millions of patients. Learn more
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Open for Submissions  Online-only and open access, npj Primary Care Respiratory Medicine is the only fully-indexed scientific journal devoted to the management of respiratory diseases in primary care. Explore the benefits of submitting your next research article.
Advertisement
MEDTECH DEALMAKERS  A supplement to Nature Biotechnology | Nature Medicine | Nature Reviews Drug Discovery This first-of-its-kind partnering journal is a must read for all medical technology professionals. The latest issue showcases innovative companies seeking partners, and in-depth analysis of dealmaking strategies and trends of the growing med tech industry. Download the issue for FREE
Comment: Organizational effectiveness: a key to R&D productivity Peter Tollman, Valery Panier, Diana Dosik, Paul Biondi & Francis Cuss p441 | doi:10.1038/nrd.2016.91 While the pharmaceutical industry overall has faced huge challenges in drug R&D in recent years, some major companies have consistently been much more productive than average. Here, we highlight 'organizational effectiveness' as a key factor underlying this superior performance and explain how it can be enhanced. Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
Biomarker search illuminates cancer immune biology Katie Kingwell p443 | doi:10.1038/nrd.2016.131 The search for better immunotherapy biomarkers is forcing the field to reconsider how it classifies cancers, with implications for the next wave of combination studies. PDF
Two pioneering osteoporosis drugs finally approach approval Ken Garber p445 | doi:10.1038/nrd.2016.132 Novel drugs from Amgen/UCB and Merck & Co. decouple bone formation from bone resorption, acting on targets genetically validated over two decades ago. PDF
NEWS IN BRIEF Biotech R&D spend jumps by more than 15% Asher Mullard p447 | doi:10.1038/nrd.2016.135 PDF
Parsing clinical success rates Asher Mullard p447 | doi:10.1038/nrd.2016.136 PDF
EMA provides first glimpse of PRIME candidates Asher Mullard p447 | doi:10.1038/nrd.2016.137 PDF
BIOBUSINESS BRIEFS Patent Watch: Nanomedicine patents highlight importance of production methods Daniel Neuman & Jenna N. Chandhok p448 | doi:10.1038/nrd.2016.118 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q3 2016 Tyler Ranj p449 | doi:10.1038/nrd.2016.119 PDF
AN AUDIENCE WITH Philip Tetlock p450 | doi:10.1038/nrd.2016.112 Philip Tetlock, author of Superforecasting, discusses how the pharmaceutical industry can make better predictions. PDF
FROM THE ANALYST'S COUCH The HIV therapy market Steven I. Gubernick, Nuno Félix, Dolim Lee, Jing J. Xu & Bashar Hamad p451 | doi:10.1038/nrd.2016.69 Key emerging therapies for HIV include novel combination regimens as well as extended-duration antiretroviral drugs. This article provides an overview of novel drugs and combinations in the pipeline, as well as an analysis of the current HIV drug market. PDF
RESEARCH HIGHLIGHTS Top Obesity: Neurotensin inhibition prevents weight gain p453 | doi:10.1038/nrd.2016.121 PDF Blood diseases: Immunotoxins till the soil for stem cell transplantation p454 | doi:10.1038/nrd.2016.130 PDF Cancer: Bivalent mTOR inhibitors — the next generation p454 | doi:10.1038/nrd.2016.134 PDF Anticancer drugs: Brain metastasis bridges the gap p455 | doi:10.1038/nrd.2016.138 PDF Metabolic disease: FGF1 stops diabetes in its tracks p456 | doi:10.1038/nrd.2016.122 PDF IN BRIEF Alzheimer disease: Antimicrobial role of amyloid-β | Depression: Understanding ketamine action | Drug design: Eliminating adverse effects of oestrogen therapy | Autoimmune disease: Reversing systemic lupus erythematosus PDF Drug Discovery JOBS of the week Postdoctoral Researcher Fellow in Drug Delivery University of Rhode Island More Science jobs from Drug Discovery EVENT 17th International Conference on Alzheimer's Drug Discovery 12.09.16 Jersey City, USA More science events from
Advertisement
Droplet Digital™ PCR (ddPCR™) is leading the way Droplet Digital PCR has led to more publications and discoveries than any other digital PCR platform - over 400 studies have taken advantage of ddPCR technology. Find out how
PERSPECTIVES		Top
OPINION Evolution of strategies to improve preclinical cardiac safety testing Gary Gintant, Philip T. Sager & Norman Stockbridge p457 | doi:10.1038/nrd.2015.34 This article discusses evolving preclinical strategies for detecting drug-induced cardiotoxicity using human ion-channel assays, human-based in silico reconstructions and human stem cell-derived cardiomyocytes. Such strategies have the potential to improve the early detection of genuine cardiotoxicity risks, reducing the likelihood of mistakenly discarding viable drug candidates and speeding worthy drugs into clinical trials. Abstract | Full Text | PDF
Advertisement
Nature Outlook Open Innovation In the competitive world of drug discovery and development, secrecy is no longer as important as it was. As it has become more difficult and costly to produce therapies, competitors have begun to view greater collaboration and openness as a way to improve the efficiency of research. Available free online Produced with support from Boehringer Ingelheim
REVIEWS		Top
Emerging applications of metabolomics in drug discovery and precision medicine David S. Wishart p473 | doi:10.1038/nrd.2016.32 Metabolomics is rapidly emerging as an important tool in understanding disease mechanisms and identifying novel therapeutic strategies. Here, Wishart explores recent developments in metabolomics technologies, focusing on the growing role of metabolomics in drug discovery and its potential effect on precision medicine. Abstract | Full Text | PDF
Altering the course of schizophrenia: progress and perspectives Mark J. Millan, Annie Andrieux, George Bartzokis, Kristin Cadenhead, Paola Dazzan, Paolo Fusar-Poli, Jürgen Gallinat, Jay Giedd, Dennis R. Grayson, Markus Heinrichs, René Kahn, Marie-Odile Krebs, Marion Leboyer, David Lewis, Oscar Marin, Philippe Marin, Andreas Meyer-Lindenberg, Patrick McGorry, Philip McGuire, Michael J. Owen, Paul Patterson, Akira Sawa, Michael Spedding, Peter Uhlhaas, Flora Vaccarino, Claes Wahlestedt & Daniel Weinberger p485 | doi:10.1038/nrd.2016.28 Advances in the understanding of the genetic and environmental causes of schizophrenia, and their relationship to aberrant patterns of neurodevelopment, have led to growing interest in the possibility that 'disease-modifying' strategies could alter the course to — and of — this debilitating disorder, rather than just alleviating its symptoms. This article provides a broad-based consideration of the challenges and opportunities inherent in such efforts. Abstract | Full Text | PDF | Supplementary information
Erratum: Reining in the supersized Phase I cancer trial Asher Mullard p516 | doi:10.1038/nrd.2016.129 Full Text | PDF
CORRESPONDENCE		Top
Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework Oriana Ciani, Marc Buyse, Mike Drummond, Guido Rasi, Everardo D. Saad & Rod S. Taylor p516 | doi:10.1038/nrd.2016.81 Full Text | PDF
Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets Anton Bespalov, Thomas Steckler, Bruce Altevogt, Elena Koustova, Phil Skolnick, Daniel Deaver, Mark J. Millan, Jesper F. Bastlund, Dario Doller, Jeffrey Witkin, Paul Moser, Patricio O'Donnell, Ulrich Ebert, Mark A. Geyer, Eric Prinssen, Theresa Ballard & Malcolm Macleod p516 | doi:10.1038/nrd.2016.88 Full Text | PDF | Supplementary information
Advertisement
Nature Publishing Group offers a free open access funding support service to enable authors to discover and apply for article processing charge funding available to them. Visit our website for further advice on the funding options available, and guidance in approaching funders and institutions, or email openaccess@nature.com for more information.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2015 Journal Citation Report (Thomson Reuters, 2015)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.